 SANTA MONICA, Calif., July 12, 2021 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT, a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Matthew Ruth as Chief Commercial Officer. Mr. Ruth brings significant commercial experience to Opiant, including leading the highly successful launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration FDA to treat opioid overdose. Mr. Ruth will begin his employment with Opiant effective today and report directly to Dr. Roger Crystal, President and CEO. 